We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ARAB HEALTH - INFORMA

Download Mobile App




Events

27 Jan 2025 - 30 Jan 2025
15 Feb 2025 - 17 Feb 2025

First-Ever AI Test for Early Diagnosis of Alzheimer’s to Be Expanded to Diagnosis of Parkinson’s Disease

By HospiMedica International staff writers
Posted on 05 Nov 2021
Print article
Illustration
Illustration

A new partnership will accelerate development of the industry’s first predictive device for Alzheimer’s Disease to be expanded to diagnosis of Parkinson’s disease.

Altoida, Inc. (Washington, DC, USA) has entered into a collaboration with the Bioinformatics and Human Electrophysiology Laboratory (BiHELab), Department of Informatics, at the Ionian University (Corfu, Greece) to investigate Altoida’s medical device, an FDA Breakthrough Device being developed for early diagnosis and monitoring of Alzheimer’s disease, for early diagnosis and prediction of Parkinson’s disease onset. BiHELab is a research center specializing in the application of mathematical modeling and machine learning techniques to neurodegenerative diseases, like Parkinson’s and Alzheimer’s.

With a 10-minute series of augmented reality and digital motor activities that simulate complex activities of daily living, Altoida transforms any smartphone or tablet into the world’s most powerful medical device to assess neurocognitive function. The company won Breakthrough Designation for development of their device to use artificial intelligence to help predict conversion to Alzheimer’s, and they secured funding from the Alzheimer’s Drug Discovery Foundation Diagnostics Accelerator to test their device for diagnosis in the preclinical phase of Alzheimer’s.

The three-year collaboration will kick off with the launch of the Digital Innovation HUB: Health Hub, a public-private partnership with 25 participating entities dedicated to fostering healthcare research and innovation in Greece. In that time, Altoida and BiHELab will apply and Altoida’s technology to analysis of Parkinson’s disease progression and evaluate its efficacy in diagnosing Parkinson’s in the preclinical phase.

"This is recognition of the strong clinical need for early diagnosis of Parkinson's disease, which could enable preventive and therapeutic intervention in the early stages to delay onset and improve clinical outcomes," said Ioannis Tarnanas, Ph.D., Chief Scientific Officer of Altoida. “We are excited to collaborate with BiHELab to further develop our technology, and to engage with the Health Hub’s scientific network to bring this application to life for the Greek population.”

"By applying innovative bioinformatics and machine learning techniques to clinical data, BiHeLab has aimed to identify novel biomarkers that are most indicative of risk of Parkinson’s disease,” said Professor Panagiotis Vlamos, Scientific Director at BiHELab. “For Parkinson’s patients, accurate prediction and early diagnosis could enable intervention before the extensive damage of dopaminergic neurons occurs."

Related Links:
Altoida, Inc. 
Ionian University 

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
New
Fetal and Maternal Monitor
F9 Series
New
Cannulating Sphincterotome
TRUEtome

Print article

Channels

Surgical Techniques

view channel
Image: Catheter electrodes could be successfully delivered and guided into ventricular spaces and brain surface for electrical stimulation (Photo courtesy of Rice University)

Novel Neural Interface to Help Diagnose and Treat Neurological Disorders with Minimal Surgical Risks

Traditional methods of interfacing with the nervous system typically involve creating an opening in the skull to access the brain. Researchers have now introduced an innovative technique called endocisternal... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more

Point of Care

view channel
Image: The acoustic pipette uses sound waves to test for biomarkers in blood (Photo courtesy of Patrick Campbell/CU Boulder)

Handheld, Sound-Based Diagnostic System Delivers Bedside Blood Test Results in An Hour

Patients who go to a doctor for a blood test often have to contend with a needle and syringe, followed by a long wait—sometimes hours or even days—for lab results. Scientists have been working hard to... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.